✕
Login
Register
Back to News
Personalis Presents NeXT Personal ctDNA Data At AACR 2026 Showing 100% Sensitivity In Colorectal Cancer Monitoring
Benzinga Newsdesk
www.benzinga.com
Positive 83.3%
Neg 0%
Neu 0%
Pos 83.3%
Podium presentation on NeXT Personal monitoring neoadjuvant therapy in colorectal cancer;
Real-world data from 10,000 patients reinforce industry-leading sensitivity;
Data presented for a new NeXT Personal feature for monitoring resistance mutations
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment